Keyword: Dominic Caruso

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a good idea.

Johnson & Johnson may have posted a fourth-quarter loss, but it’s just a step toward billions of dollars in cash coming home.

J&J's new meds came on strong again in Q2, helping fuel a 9% increase in pharma sales--good news for the healthcare giant as Remicade biosimilars wait in the wings.